We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra‐atrial thrombosis in severe haemophilia with an inhibitor

Weyand AC, Dorfman AL, Shavit JA, Pipe SW. Haemophilia. 2019;25(3):e203-e205.

Evaluating the economic burden associated with problem joints, across moderate and severe haemophilia A, in children and adults: CHESS Paediatrics and CHESS II

Poster Presentation ABS1148: Chowdary P, Hermans C, Asghar S et al.

Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol. 2018;183(2):257-266.

Safety of Recombinant Coagulation Factors in Treating Hemophilia.

Morfini M and Rapisarda CAP. Expert Opin Drug Saf 2019;18:75–85.    

Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK

Hassan E, Motwani J. [published online ahead of print Jun 12]. Haemophilia. 2021 Jun 12. doi: 10.1111/hae.14358

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Yoneyama K, Schmitt C, Kotani N, et al. Clin Pharmacokinet 2018;57:1123–1134.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Oldenburg J, Mahlangu JN, Kim B, et al. N Engl J Med 2017;377:809–818.

Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes

Camelo RM, de Medeiros TC, de Albuquerque DGB, Álvares-Teodoro J. [published online ahead of print May 7] Hematol Transfus Cell Ther. 2021 May 7:S2531-1379(21)00051-1. doi: 10.1016/j.htct.2021.02.010

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors

Okamoto S, Suzuki N, Suzuki A, et al. TH Open. 2019;3(4):e364-e366.

Emicizumab use in major orthopedic surgery

Seaman CD, Ragni MV. Blood Adv. 2019;3(11):1722-1724.